Catalent Breaks Ground at $112-Million Drug Product Manufacturing Facility
Catalent recently held a groundbreaking ceremony at its Bloomington, Indiana pharmaceutical fill/finish site.
Catalent recently held a ground breaking ceremony at its Bloomington, Indiana site to mark the start of construction on a $112-million drug product manufacturing facility, which will increase fill/finish capacity at the site by 79,000 ft2. The facility will house a high-speed vial line, using both ready-to-use components and bulk filling; a high-speed flexible syringe/cartridge line; a fully automated vial inspection machine; and all associated services and support areas. Catalent Biologics plans to create up to 200 new jobs to support the increased production. Completion of both construction and recruitment are expected by the end of 2024.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
